www.laserfocusworld.com is using a security service for protection against online attacks. This process is automatic. You will be redirected once the validation is complete.

Reference ID IP Address Date and Time
8c6a86724d6909bfa8e9ab8f836ba255 04/10/2021 11:40 AM UTC

Atrion Reports First Quarter Results

ALLEN, Texas, May 07, 2020 (GLOBE NEWSWIRE) -- Atrion Corporation (Nasdaq - ATRI) today announced that revenues for the quarter ended March 31, 2020 were $43.6 million compared with $41.6 million for the same period in 2019. Net income in the current-year quarter totaled $8.9 million compared to $9.4 million in last year’s first quarter, with diluted earnings per share for the first quarter of 2020 at $4.79 compared to $5.07 for the first quarter of 2019.

In announcing results for the first quarter of 2020, David A. Battat, President & CEO, said, “Before discussing our results, I wish to express my gratitude to my co-workers for their truly exceptional efforts during the COVID-19 pandemic. All of our facilities have remained operational thanks to their dedication. This was a monumental effort requiring the modification of manufacturing lines to increase distancing, scale up production capacity of critically needed products, and make personal protective equipment for our employees and for donation to our communities. Despite enormous personal and professional challenges, my co-workers accomplished all of this with courage, grace and dignity. I am privileged to work alongside them.” 

Commenting on the Company’s results for the quarter compared to the same period last year, Mr. Battat stated, “We are pleased to report a 5% growth in revenues, despite the bans on elective surgery that impacted orders for our cardiovascular products as well as our decision to phase out certain 20 year-old ophthalmic products. Revenues from our fluid delivery products, many of which are used in critical care settings, saw an increase of 23%.” Mr. Battat continued, “We are especially pleased that operating income was up 6%, despite higher manufacturing costs due to the pandemic as well as higher expenses as we increased our research and development efforts. Net income and diluted EPS were both lower by 6% due to the unfavorable impact of mark-to-market valuation of our investment portfolio. During the quarter we purchased 14,576 of our shares at an average price of $634.27 per share while continuing to hold $96.4 million in cash and short- and long- term investments as of March 31, 2020. Addressing expectations for 2020, Mr. Battat concluded, “The world changed after we provided financial guidance for 2020, requiring us to completely reassess that forecast. With the COVID-19 pandemic continuing, and the likelihood of a second wave in the fall and winter, many of our OEM and hospital customers are reporting they are uncertain about their 2020 buying patterns. We could also be affected by a lasting economic slowdown, or mass illnesses requiring us to close our operations. Given all of this volatility, the only guidance we can provide for 2020 is that we will work tirelessly to manage this crisis effectively and compassionately, and that our focus on long-term growth will be steadfast.”

Statements in this press release that are forward looking are based upon current expectations and actual results or future events may differ materially. Such statements include, but are not limited to, Atrion’s guidance for 2020. Words such as “expects,” “believes,” “anticipates,” “forecasts,” “intends,” "should", "plans," "will" and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements involve risks and uncertainties. The following are some of the factors that could cause actual results or future events to differ materially from those expressed in or underlying our forward-looking statements: the impact of the COVID-19 virus; risk that the COVID-19 virus further disrupts or causes us to cease operations; changing economic, market, and business conditions; acts of war or terrorism; the effects of governmental regulation; and the diversion of management and other resources to respond to the COVID-19 outbreak. The foregoing list of factors is not exclusive, and other factors are set forth in the Company’s filings with the Securities and Exchange Commission. The forward-looking statements in this press release are made as of the date hereof, and we do not undertake any obligation, and disclaim any duty, to supplement, update, or revise such statements, whether as a result of subsequent events, changed expectations or otherwise, except as required by applicable law.

Atrion Corporation develops and manufactures products primarily for medical applications.  The Company’s website is www.atrioncorp.com.

Contact: Jeffery Strickland
               Vice President and Chief Financial Officer
               (972) 390-9800

(In thousands, except per share data)

 Three Months Ended
March 31, 
  2020   2019 
Revenues$    43,594  $    41,614 
Cost of goods sold   23,726     22,911 
Gross profit   19,868     18,703 
Operating expenses   8,154     7,666 
Operating income   11,714     11,037 
Interest and dividend income   462     582 
Other investment income (loss)   (997)      211 
Income before income taxes   11,179     11,830 
Income tax provision   (2,281)    (2,392)
Net income   8,898     9,438 
Income per basic share$    4.80  $    5.09 
Weighted average basic shares outstanding   1,853     1,853 
Income per diluted share$    4.79  $    5.07 
Weighted average diluted shares outstanding   1,859     1,862 

(In thousands)

 Mar. 31, Dec. 31,
ASSETS 2020  2019
Current assets:   
Cash and cash equivalents$  44,080 $  45,048
Short-term investments   18,568    23,766
Total cash and short-term investments   62,648    68,814
Accounts receivable   22,813    18,886
Inventories   41,252    42,093
Prepaid expenses and other   1,367    2,545
Total current assets   128,080    132,338

Long-term investments
   33,718    31,772

Property, plant and equipment, net
   85,446    84,606
Other assets   13,186    13,315
 $  260,430 $  262,031
Current liabilities   12,961    11,274
Line of credit   --    --
Other non-current liabilities   12,472    12,887
Stockholders’ equity   234,997    237,870
 $  260,430 $  262,031

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.